Within 1C2?weeks of the injection, the AAV-Injection in the MPS I Canine Cornea (A) Corneal images prior to AAV injection and at the indicated experimental conclusion for all those MPS I dogs with early (doggie 1) and advanced (dogs 2C4) corneal diseases. cornea and in some systemic organs; however, a capsid antibody response was detected in only the highest dosed Chlorhexidine HCl subject. Collectively, the results suggest that intrastromal AAV8G9-IDUA therapy prevents and reverses visual impairment associated with MPS I corneal clouding. expression cassette was described as capable of restoring IDUA, both normal and supraphysiological levels, to main MPS I individual fibroblasts.8 Furthermore, a rationally designed adeno-associated virus (AAV) capsid, AAV8G9, was deemed most efficient for human corneal gene delivery, compared with the natural AAV serotypes, following corneal intrastromal injection.8 Corneal intrastromal administration of AAV8G9 vectors in wild-type (WT) rabbits culminated in expansive transduction with transgene expression found in all major corneal layers spanning the epithelium, stroma, and endothelium.9 Even though Chlorhexidine HCl human and WT rabbit experiments optimized corneal gene delivery via AAV8G9-cytomegalovirus?(CMV)-human (AAV-gene addition in the most relevant naturally occurring large-animal model, the MPS I canine.2,10, 11, 12, 13, 14 The data obtained from the canine MPS I model demonstrate that: (1) intrastromal AAV vector injections in MPS I corneas were well tolerated, (2) intrastromal AAV-reversed MPS I corneal clouding in advanced disease, and (3) intrastromal AAV-prevented progression of early MPS I corneal disease while reversing the early changes. Remarkably, at all tested doses, phenotypic recovery was apparent within weeks following a single vector injection and was largely sustained to the study endpoint, 25?weeks post-injection. Other than a delayed-onset corneal edema, which was inconsistent and transient, no complications were noted, and biodistribution studies exhibited that although vector genomes were detected in extraocular tissues, only the highest administered dose resulted in a capsid neutralizing antibody response. The collective efficacy and security data of intrastromal AAV-in MPS I canine corneas warrant the continued examination of this technology as a potential single-dose cure to restore vision in MPS I patients Chlorhexidine HCl affected with corneal clouding. Results To investigate the therapeutic efficacy and tolerability of AAV-gene therapy for MPS I corneal disease, we employed Chlorhexidine HCl a naturally occurring canine model (vectors, made up of a previously reported Rabbit Polyclonal to MASTL codon-optimized human cDNA,8 were injected into the canine corneal stroma with increasing volume (50C80?L) in different animals, resulting in escalating viral dose ranging from 5e10 to 8e10 viral genomes (vg) per cornea (Table 1). In these experiments, the contralateral vision injected with AAV vectors encoding the green fluorescent protein (GFP) served as a control (Table 1). Table 1 Summary of the MPS I Animals, AAV Vector Injections, and Clinical End result can prevent the progression into advanced corneal disease, the younger MPS I canine with early corneal disease received a single intrastromal injection in each cornea (5e10 vg; Table 1). The deposition of the vector answer resulted in immediate opacity and increased thickness of the cornea consistent with focal edema (Physique?S2), which is common to all clinical corneal intrastromal injections. Clarity and central corneal thickness (CCT) returned to pre-injection values within 24?h as observed clinically and by ultrasound biomicroscopy (Physique?S2). Within 1C2?weeks of the injection, the AAV-Injection in the MPS I Canine Cornea (A) Corneal images prior to AAV injection and at the indicated experimental conclusion for all those MPS I dogs with early (doggie 1) and advanced (dogs 2C4) corneal diseases. (B) Long-term restoration of near-normal central corneal thickness (CCT) in the AAV-at advanced disease (dogs 2C4), sustained throughout the follow-up period. Doggie 1 that was treated at early disease developed minimal vascularization in the AAV-can reverse diffuse pre-existing corneal clouding. Again, the AAV vector injections were well tolerated in the corneas of all three older subjects (subjects 2C4), and focal corneal edemas associated with the injection resolved to pre-injection values over a 22- to 48-h period (Physique?S2). The.
Recent Posts
- had written the first draft manuscript
- (E-F) Neither full-length nor truncated mutant IKK(R286X) protein is detectable in patients (PT), siblings, and normal peripheral blood mononuclear cells (E) and EBV-transformed B cells (F) by immunoblotting analysis with anti-N- and anti-C-terminal IKK antibodies
- Indeed, the demonstration of superantigen activity has been the standard for detecting MMTV contamination in mice because PCR cannot distinguish genomic viral RNA from endogenously-expressed MMTV transcripts, and mice infected by breast milk have suboptimal neutralizing antibody responses [78,82]
- Third, N-terminal tagging of MLKL substances, making them not capable of triggering necrotic loss of life,7, 16 didn’t prevent their translocation towards the nuclei in response to TBZ (Body 1c)
- Cells were seeded in 60-mm plates and cultured to 80C90% confluence
Recent Comments
Archives
- October 2024
- September 2024
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
Categories
- Orexin Receptors
- Orexin, Non-Selective
- Orexin1 Receptors
- ORL1 Receptors
- Ornithine Decarboxylase
- Orphan 7-TM Receptors
- Orphan 7-Transmembrane Receptors
- Orphan G-Protein-Coupled Receptors
- Orphan GPCRs
- OT Receptors
- Other Acetylcholine
- Other Adenosine
- Other Apoptosis
- Other ATPases
- Other Calcium Channels
- Other Channel Modulators
- Other Dehydrogenases
- Other Hydrolases
- Other Ion Pumps/Transporters
- Other Kinases
- Other MAPK
- Other Nitric Oxide
- Other Nuclear Receptors
- Other Oxygenases/Oxidases
- Other Peptide Receptors
- Other Pharmacology
- Other Product Types
- Other Proteases
- Other RTKs
- Other Synthases/Synthetases
- Other Tachykinin
- Other Transcription Factors
- Other Transferases
- Other Wnt Signaling
- OX1 Receptors
- OXE Receptors
- Oxidative Phosphorylation
- Oxoeicosanoid receptors
- Oxygenases/Oxidases
- Oxytocin Receptors
- P-Glycoprotein
- P-Selectin
- P-Type ATPase
- P-Type Calcium Channels
- p14ARF
- p160ROCK
- P2X Receptors
- P2Y Receptors
- p38 MAPK
- p53
- p56lck
- p60c-src
- p70 S6K
- p75
- p90 Ribosomal S6 Kinase
- PAC1 Receptors
- PACAP Receptors
- PAF Receptors
- PAO
- PAR Receptors
- Parathyroid Hormone Receptors
- PARP
- PC-PLC
- PDE
- PDGFR
- PDK1
- PDPK1
- Peptide Receptor, Other
- Peptide Receptors
- Peroxisome-Proliferating Receptors
- PGF
- PGI2
- Phosphatases
- Phosphodiesterases
- Phosphoinositide 3-Kinase
- Phosphoinositide-Specific Phospholipase C
- Phospholipase A
- Phospholipase C
- Phospholipases
- Phosphorylases
- Photolysis
- PI 3-Kinase
- PI 3-Kinase/Akt Signaling
- PI-PLC
- PI3K
- Pim Kinase
- Pim-1
- PIP2
- Pituitary Adenylate Cyclase Activating Peptide Receptors
- PKA
- PKB
- PKC
- PKD
- PKG
- PKM
- PKMTs
- PLA
- Plasmin
- Platelet Derived Growth Factor Receptors
- Platelet-Activating Factor (PAF) Receptors
- Uncategorized